Skip to content

Study of short-term treatment compliance, effectiveness evaluation and online questionnaire follow-up of obstructive sleep apnea syndrome through nasopharyngeal airway

Study of short-term treatment compliance, effectiveness evaluation and online questionnaire follow-up of obstructive sleep apnea syndrome through nasopharyngeal airway

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043891
Enrollment
Unknown
Registered
2021-03-04
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstructive sleep apnea syndrome

Interventions

Nasopharyngeal Airway Treatment Group :Treatment and follow-up with the nasopharyngeal airway
Best Supportive Treatment Group:The best supportive treatment in that the otolaryngologist will give the most commonly used clinical treatment methods and recommendations: including sleep hygiene, nap

Sponsors

the Sixth People's Hospital affiliated to Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years; 2. Snoring more than 5 days a week, and repeatedly hold the breath or open the mouth to breathe during sleep; 3. OSA patients with 0-2 degrees Friedman tonsils and 1-2 degrees Friedman tongue position diagnosed by laboratory standard polysomnography; 4. Willing to use nasal cavity devices, voluntarily participate in this clinical study, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Patients with nasal polyps and nasal ventilation disorders; patients with nasal bleeding or bleeding tendency; patients with nasal trauma, nasal cavity deformity, infection or wound in the nasal cavity; patients with severe nasal septum, nasal obstruction, fractures and skull base fractures; patients with cerebrospinal fluid rhinorrhea ; Patients with coagulopathy (risk of nose bleeding); 3. Cardio-cerebrovascular diseases (hypertension, recurrent atrial fibrillation, left heart failure, coronary artery disease and stroke); respiratory diseases (respiratory failure, COPD); mental and neurological diseases (epilepsy); advanced cancer and chronic inflammatory diseases; 4. Silicone allergy (the nasopharyngeal airway used in this study contains this ingredient); 5. Acute upper respiratory tract infection; 6. The investigator believes that there are any reasons not suitable for participating in the trial.

Design outcomes

Primary

MeasureTime frame
AHI index and lowest oxygen saturation;

Secondary

MeasureTime frame
physical index;usage time;blood test index;

Countries

China

Contacts

Public ContactYi Hongliang

The Sixth People's Hospital affiliated to Shanghai Jiao Tong University

yihongl@126.com+86 18930172215

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026